Immunotherapeutic strategies in gastroenteropancreatic neuroendocrine neoplasms: present condition and future developments
- 25 May 2026
- journal article
- review article
- Published by Taylor & Francis in Journal of Chemotherapy
- p. 1-17
Abstract
Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) are heterogeneous malignancies frequently resistant to standard therapies. Immunotherapy represents a novel management frontier. This review synthesises clinical and translational evidence regarding immune checkpoint inhibitors (ICIs), bispecific T-cell engagers, chimeric antigen receptor (CAR) T-cell therapies, and oncolytic virotherapy in GEP-NENs. We examine critical antigenic targets (somatostatin receptors, DLL3) and strategies to overcome the immunosuppressive tumour immune microenvironment (TIME). While single-agent ICIs show modest efficacy in well-differentiated NETs, dual checkpoint blockade exhibits durable disease control in poorly differentiated NECs. Targeted modalities like DLL3-directed bispecific antibodies demonstrate significant early efficacy. Furthermore, we summarise highly synergistic combinatorial approaches, specifically integrating immunotherapy with anti-angiogenic agents and peptide receptor radionuclide therapy (PRRT). Ongoing biomarker-driven trials and molecular profiling remain essential to optimise patient selection and treatment sequencing.Keywords
This publication has 79 references indexed in Scilit:
- Efficacy and safety of HBM4003 combined with toripalimab in refractory neuroendocrine neoplasms: a multicenter, phase II studyeClinicalMedicine, 2025
- Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 studyAnnals of Oncology, 2022
- Assessment of Clinical Response Following Atezolizumab and Bevacizumab Treatment in Patients With Neuroendocrine TumorsJAMA Oncology, 2022
- Overview of the 2022 WHO Classification of Neuroendocrine NeoplasmsEndocrine Pathology, 2022
- The molecular link between oxidative stress, insulin resistance, and type 2 diabetes: A target for new therapies against cardiovascular diseasesCurrent Opinion in Pharmacology, 2022
- Immunotherapy for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a 2021 updateCancer Immunology, Immunotherapy, 2021
- "Present and future of immunotherapy in Neuroendocrine Tumors"Reviews in Endocrine and Metabolic Disorders, 2021
- Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin‐remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2DThe Journal of Pathology, 2016
- Immunologic response to the survivin-derived multi-epitope vaccine EMD640744 in patients with advanced solid tumorsCancer Immunology, Immunotherapy, 2014
- SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours (GEP NETS)Clinical and Translational Oncology, 2011